Single daily dose penbutolol in the treatment of hypertension: A double blind crossover comparison with propranolol

1980 ◽  
Vol 17 (6) ◽  
pp. 409-413 ◽  
Author(s):  
M. M. Kubik ◽  
G. W. Hanks
Keyword(s):  
Single Daily Dose ◽  
Double Blind ◽  
Daily Dose ◽  
Treatment Of Hypertension ◽  
Crossover Comparison

Ciprofloxacin for the Treatment of Cholera: A Randomized, Double-Blind, Controlled Clinical Trial of a Single Daily Dose in Peruvian Adults

1995 ◽  
Vol 20 (6) ◽  
pp. 1485-1490 ◽  
Author(s):  
E. Gotuzzo ◽  
C. Seas ◽  
J. Echevarria ◽  
C. Carrillo ◽  
R. Mostorino ◽  
...  
Keyword(s):  
Clinical Trial ◽  
Single Daily Dose ◽  
Controlled Clinical Trial ◽  
Double Blind ◽  
Daily Dose

Effects of Allopurinol (Zyloric®) in Patients with Long-Term Indwelling Urethral Catheters

1983 ◽  
Vol 11 (2) ◽  
pp. 116-119 ◽  
Author(s):  
Allan Eddeland ◽  
Hans Hedelin
Keyword(s):  
Single Daily Dose ◽  
Hospitalized Patients ◽  
Blind Study ◽  
Double Blind Study ◽  
Double Blind ◽  
Indwelling Catheters ◽  
Catheter Encrustation ◽  
Daily Dose

A randomized double-blind study of the effect of allopurinol on the need for catheter attention and the amount of catheter encrustation has been conducted in hospitalized patients with long-term indwelling catheters. Allopurinol 300 mg as a single daily dose significantly reduced the frequency of need for catheter attention including catheter change. There was no significant effect on the quantity of catheter encrustation.

Nadolol and Propranolol in the Treatment of Hypertension: A Double-Blind Comparison

1980 ◽  
Vol 8 (3) ◽  
pp. 193-198 ◽  
Author(s):  
M M El Mehairy ◽  
MB Cairo ◽  
A Shaker ◽  
M Ramadan ◽  
S Hamza ◽  
...  
Keyword(s):  
Adverse Reactions ◽  
Statistical Significance ◽  
Randomized Study ◽  
Double Blind ◽  
Once Daily ◽  
Depressant Action ◽  
Daily Dose ◽  
Treatment Of Hypertension ◽  
Blind Comparison ◽  
Supine Systolic Blood Pressure

Nadolol and propranolol were compared in seventy-five hypertensive patients in a double-blind randomized study conducted at Ain-Shams Hospital. After an initial wash-out period of 5 weeks, including 3 weeks of placebo administration, forty-five patients were given nadolol once daily and thirty patients received propranolol four times per day for 12 weeks, followed by a tapering-off period of 2 weeks. Both beta-blocking agents were effective in controlling hypertension with final daily doses ranging from 80 to 320 mg. Of statistical significance, however, were the better responses of supine systolic blood pressure elicited by nadolol. The only adverse reactions that occurred in this series were slight weight gains in two patients treated with nadolol and moderate dizziness in one patient treated with propranolol. Nadolol was proved to be a safe antihypertensive drug, at least comparable to propranolol in efficacy, with the advantages of a once-daily dose and a lack of direct depressant action on the heart.

Trial of a Sustained Release Form of Amitriptyline in the Treatment of Depressive Illness

1972 ◽  
Vol 120 (554) ◽  
pp. 65-67 ◽  
Author(s):  
A. C. P. Sims
Keyword(s):  
Failure Rate ◽  
Tricyclic Antidepressants ◽  
Psychiatric Patients ◽  
Depressive Illness ◽  
Single Daily Dose ◽  
High Failure Rate ◽  
Double Blind ◽  
Daily Dose ◽  
Release Form ◽  
Patient Studies

Amitriptyline is a widely used antidepressant and its effectiveness has been shown, e.g. in comparison with imipramine in double blind trial (Burt et al., 1962; Hordern et al., 1963, 1964). A disadvantage of currently prescribed tricyclic antidepressants is the necessity for administering the drug three times a day. It has been shown that general medical and in particular psychiatric patients fail to take their medication either in the prescribed dose or at all (Benstead and Theobald, 1952; Haler, 1952; Park and Lipman, 1964; Parkes et al., 1962; Porter, 1969). This failure rate may be as high as 50 per cent (Dixon et al., 1957; Willcox et al., 1965). Even in psychiatric in-patient studies there was still a high failure rate in taking prescribed psychiatric drugs (Hare and Willcox, 1967). A regimen consisting of a single daily dose is more reliably taken than one consisting of thrice daily dosage (Coppen et al., 1969; General Practitioner Clinical Trial 1970).

scholarly journals A Double-Blind Comparison of Single Daily Dose of Imipramine at Bedtime with T.I.D. Dosage of Imipramine

1980 ◽  
Vol 3 (2) ◽  
pp. 97-100
Author(s):  
N. Janakiramaiah ◽  
S. A. Srikhande ◽  
R. L. Kapur ◽  
D. K. Subbakrishna
Keyword(s):  
Single Daily Dose ◽  
Double Blind ◽  
Daily Dose ◽  
Blind Comparison

Comparative Antihypertensive Effects of Guanabenz and Clonidine

1982 ◽  
Vol 10 (1) ◽  
pp. 6-14 ◽  
Author(s):  
Barry R Walker ◽  
Larry E Hare ◽  
Marc W Deitch
Keyword(s):  
Blood Pressure ◽  
Adverse Effects ◽  
Diastolic Blood Pressure ◽  
Single Daily Dose ◽  
Double Blind Trial ◽  
Double Blind ◽  
Hypertensive Patients ◽  
Safety And Efficacy ◽  
Daily Dose ◽  
Clinically Significant

The safety and efficacy of guanabenz and clonidine were compared in 188 hypertensive patients during a 6-month double-blind trial. Mean supine diastolic blood pressure (SDBP) decreased from 103 to 88 mm Hg (p < 0.01) among guanabenz patients and from 101 to 88 mm Hg (p < 0.01) among clonidine patients who completed 6 months of b.i.d. therapy. Clinically significant individual SDBP decreases occurred in 85% of the guanabenz patients and in 83% of the clonidine patients after 6 months. Adverse effects, consisting primarily of drowsiness, dry mouth, dizziness, and weakness, were similar in the two therapy groups. The responses obtained with guanabenz (b.i.d.) were maintained, along with a decrease in adverse effects, by an equivalent single daily dose of guanabenz during a second 6 months of therapy. Seventy-six per cent (13/17) of the patients whose blood pressure was not adequately controlled by guanabenz alone after 8 weeks of therapy subsequently responded to a combination of guanabenz and hydrochlorothiazide. Similarly, 85% (17/20) of the patients who failed to respond to clonidine alone subsequently responded to guanabenz either alone or in combination with hydrochlorothiazide. These results suggest that guanabenz or the combination of guanabenz and hydrochlorothiazide is effective therapy for the majority of hypertensive patients.

Dihomo-γ-Linolenic Acid in Patients with Atherosclerosis: Effects on Platelet Aggregation, Plasma Lipids and Low-Density Lipoprotein-Induced Inhibition of Prostacyclin Generation

1984 ◽  
Vol 51 (02) ◽  
pp. 186-188 ◽  
Author(s):  
A Szczeklik ◽  
R J Gryglewski ◽  
K Sladek ◽  
E Kostka-Trąbka ◽  
A Żmuda
Keyword(s):  
Linolenic Acid ◽  
Plasma Lipids ◽  
Low Density Lipoprotein ◽  
Density Lipoprotein ◽  
Thromboxane A2 ◽  
Low Density ◽  
Red Cell ◽  
Double Blind ◽  
Daily Dose ◽  
Antithrombotic Effects

SummaryDihomo-γ-linolenic acid (DHLA), a precursor of monoenoic anti-aggregatory prostaglandins (PGE1, PGD2), was administered for 4 weeks in a daily dose of 1.0 g into 33 patients with atherosclerosis on a basis of a double-blind trial. Comparison of treatment and placebo groups revealed elevation of DHLA in red cell lipids in DHLA-treated subjects. No differences, however, between the two groups could be observed in platelet aggregability, thromboxane A2 generation by platelets, serum cholesterol, PGE1 and PGE2 levels, and in inhibitory activity of low-density lipoproteins against prostacyclin synthetizing system in arteries. The dietary supplementation used did not lead to distinct antithrombotic effects.

Sign in / Sign up

Export Citation Format

Share Document